Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Wedbush Assumes Ultragenyx Pharma (RARE) at Outperform
February 17, 2017 12:09 PM ESTWedbush assumed coverage on Ultragenyx Pharma (NASDAQ: RARE) with an Outperform rating and a price target of $88.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $76.82 yesterday.
... MoreJefferies Reiterates Buy Rating and $109 PT on Ultragenyx (RARE) Following 'Uneventful' 4Q16 Results
February 17, 2017 8:13 AM ESTJefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across multiple initiatives, despite an "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.
Wang comments, "RARE 4Q16 EC was largely... More
Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c
February 16, 2017 4:13 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More